. /.WORLD TRADE
ORGANIZATIONG/TBT/N/FIN/3
13 September 2001
(01-4320)
Committee on Technical Barriers to Trade Original:  English
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6.
1. Member to Agreement notifying:   FINLAND
If applicable, name of local government involved (Articles 3.2 and 7.2):           
2. Agency responsible:   National Agency for Medicines / Finland        
Name and address (including telephone and fax numbers, e-mail and web-site
addresses, if available) of  agency or authority designated to handle comments
regarding the notification shall be indicated if different from above:
Mrs. Hanna-Maija Koponen-Piironen
Mannerheimintie 166
PL 55
00301 Helsinki
Tel.: +358-9-47334 218
Fax: +358-9-47334 267
email: Hanna-Maija.Koponen@nam.fi
www.nam.f i
3. Notified under Article 2.9.2 [ X], 2.10.1 [    ], 5.6.2 [    ], 5.7.1 [    ], other:           
4. Products covered (HS or CCCN where applicable, otherwise national tariff heading.
ICS numbers may be provided in addition, where applicable):   Medicinal products
5. Title, number of pages and language(s) of the notified document:   Importation of
Medicinal Products for Personal use (5 pages, in Finnish)        
6. Description of content:     The purpose of this draft administrative regulation is to state
specific provisions concerning the personal import of medicinal products.  With this
regulation it is possible to control the amounts of medicinal products which are imported bythe private persons who have been travelling abroad.  Via this kind of control it is possible
to ensure that there will not be illegal import of medicinal products into Finland which
might happen when people are travelling abroad.  For example this draft regulation have a
paragraph which states that an individual is allowed to import Finland only three months
need of personal medicinal products when he or she is coming outside of European TradeArea (ETA) .  In case of travelling in ETA the amount to import is a personal need for a year.
The medicinal products should have a legal basis at importing country which can be proved
e.g. by personal prescription and the product should also have a legal pharmaceutical
distributor in exporting country.         
7. Objective and rationale, including the na ture of urgent problems where applicable:
Protection of consumersG/TBT/N/FIN/3
Page 2
8. Relevant documents:
9. Proposed date of adoption:
Proposed date of entry into force: }To be determined
10. Final date for comments:   6 December 2001
11. Texts available from:  National enquiry point [ X] or address, telephone and fax
numbers, e-mail and web-site addresses, if available of the other body:           